Recent advances in irreversible kinase inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Resurgence in interest in irreversible kinase inhibitors despite concerns.
• Irreversible inhibitors offer key advantages over reversible counterparts.
• Over 60 patent applications disclosed in the past 4 years.

Purpose of the Study:

• Review patent literature from 2010-2013.
• Disclose and discuss novel irreversible kinase inhibitors.
• Highlight potential therapeutic applications.

Main Methods:

• Patent literature review (2010-2013).
• Identification of novel irreversible kinase inhibitors.
• Discussion of target kinases and therapeutic indications.

Main Results:

• Novel irreversible inhibitors identified for Bruton's tyrosine kinase, epidermal growth factor receptor, Janus kinase 3, and phosphoinsitide 3.
• These inhibitors show potential for treating mantle cell lymphoma, non-small-cell lung cancer, autoimmune disorders, and metastatic cancers.
• Discussion of clinical success likelihood and future applications.

Conclusions:

• Irreversible kinase inhibitors represent a promising therapeutic strategy.
• Novel agents offer new treatment options for various cancers and autoimmune diseases.
• Further clinical development is warranted to realize their full potential.